 The selected countries were the first five countries to launch TrobaltTM Germany, Denmark, United Kingdom, Switzerland and Sweden and an additional three countries with launch in 2011, but with relatively high rates of uptake of TrobaltTM Spain, Slovakia and Norway. The selection of countries includes Switzerland, which is not part of the European Union. However, the key messages regarding the risks with TrobaltTM are in alignment. The rationale for surveying the first five countries to launch is so that any issues identified from these countries regarding the effectiveness of the Physicians Guide and PIL in communicating the risks of TrobaltTM can be addressed as soon as possible, and the key messages can be revised in a timely manner. In addition, these countries are likely to provide the greatest number of neurologists with experience of prescribing TrobaltTM, and their patients. 